Maritime navigation fitness: An objective medical risk assessment;L'aptitude à la navigation maritime: Une véritable évaluation des risques de maladie

Archives des Maladies Professionnelles et de l'Environnement

Volumn 66, Issue 4, 2005, Pages 318-325

  Jegaden D ^a   Dewitte, J D ^b   Lodde B ^b  

^a Service Interprofessionnel de Santé au Travail de la Région Brestoise   (France)

^b CHU MORVAN   (France)

Author keywords

Evidence based medicine; Fitness to work; Maritime medicine; Ships

Indexed keywords

ARTICLE; EVIDENCE BASED MEDICINE; FITNESS; HUMAN; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; OCCUPATIONAL DISEASE; OCCUPATIONAL MEDICINE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SHIPPING; WORK CAPACITY; WORK ENVIRONMENT;

EID: 26844461410     PISSN: 17758785     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1775-8785(05)79100-1     Document Type: Article

References (13)

1. Glasziou P., Guyatt G., Dans A.L., et al.: Applying the results of trials and systematic reviews to individual patients. ACP Journal Club, 1998; 129: 17-18.
2. Pujos M.: Prise en charge des problèmes cardiaques à bord des navires. Expertise du CCMM. Actes du Colloque «Mer et Sante» Ifremer Ed., Brest, 2004.
3. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyorala K.: Prevention of coronary heart disease in clinical practice. Recommandations of the Second JointTask Force of European and other Societies on Coronary Prevention. Eur. Heart J., 1998; 19: 1434-1503.
4. Roncalli J., Richez F., Galinier M., et al.: Scores pronostiques pour la revascularisation des myocardiopathies ischémiques. Ann. Cardiol. Angéiol, 2004; 53: 177-187.
5. Linkins LA. Choi P.T., Douketis J.M.: Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromoembolism. A meta-analysis. Ann. Intern. Med., 2003; 139: 893-900.
6. Diener H.C., Bogousslavsky J., Brass L.M., et al.: Aspirin and clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. E. Heart J., 2004; 25 (13): 1163-1170.
7. Agema W.R, Monraats P.S., Zwinderman A.M., et al.: Current PCLA practice and clinical outcomes in The Netherland: the real world in the pre-drug-eluting stent era, Eur. Heart J., 2004; 25: 1163-1170.
8. Morice M.C., Serruys P., Sousa E., et al.: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med., 2002; 643: 1773-1780.
9. Stankovic G., Colombo A., Bersin R., et al.: Comparison of directional coronary atherctomy and stenting versus stenting alone for the treatment of de novo and restenotic coronary artery narrowing. Am. J. Cardiol., 2004; 93: 953-958.
10. Schiele T., Pöllinger B., Kantlehner R., et al.: Evolution of angiographic restenosis rate and late lumen loss after intracoronary beta radiation for in-stent restenotic lesions. Am. J. Cardiol., 2004; 93: 836-842.
11. Holmes D., Leon M., Moses J., et al.: Analysis of 1-year clinical outcomes in the SIRIUS trial. Circulation, 2004; 109: 634-640.
12. Cutlip D., Chhabra A., Baim D. et al.: Beyond restenosis. Five-year clinical outcomes from second generation coronary stent trials. Circulation, 2004; 110: 1226-1230.
13. Marie Y., Jégaden D.: Artériopathie oblitérante des membres inférieurs chez les gens de mer. Importance, facteurs de risque et aptitude à la navigation. Arch. Mal. Prof., 1991; 52, 5: 327-332.